Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the ...

Axios Visuals The number of prescriptions for GLP-1 drugs jumped roughly 10% in 2024, according to insurance claims data provided to Axios by health analytics company PurpleLab. Why it matters: The ...

I tried anti-obesity medication and these were the surprising side-effects' - When Henry Conway hit his forties his BMI ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

I applaud the Biden administration’s recent moves to make these anti-obesity drugs more accessible to people on Medicaid and ...

Elon Musk has admitted to taking a weight-loss drug in a Christmas Day post on X, formerly Twitter, as he shared a picture of ...

Anti-obesity medication use was associated with reduced alcohol consumption among patients in a telehealth medical weight ...

The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s.

Ozempic and Wegovy are two popular injectable medications for weight loss and diabetes. But what’s the difference?

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications.